Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics


Trillium Therapeutics Inc. (TRIL): $17.53

0.08 (+0.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRIL POWR Grades


  • Value is the dimension where TRIL ranks best; there it ranks ahead of 43.68% of US stocks.
  • The strongest trend for TRIL is in Momentum, which has been heading down over the past 48 weeks.
  • TRIL's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

TRIL Stock Summary

  • The ratio of debt to operating expenses for Trillium Therapeutics Inc is higher than it is for about just 5.84% of US stocks.
  • With a price/sales ratio of 42,535.26, Trillium Therapeutics Inc has a higher such ratio than 99.88% of stocks in our set.
  • As for revenue growth, note that TRIL's revenue has grown -79.8% over the past 12 months; that beats the revenue growth of merely 2% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Trillium Therapeutics Inc, a group of peers worth examining would be INMB, NYMX, CVM, BLU, and ZOM.
  • TRIL's SEC filings can be seen here. And to visit Trillium Therapeutics Inc's official web site, go to www.trilliumtherapeutics.com.

TRIL Valuation Summary

  • In comparison to the median Healthcare stock, TRIL's EV/EBIT ratio is 64.51% higher, now standing at 48.2.
  • Over the past 87 months, TRIL's EV/EBIT ratio has gone up 45.
  • TRIL's price/earnings ratio has moved up 53.5 over the prior 87 months.

Below are key valuation metrics over time for TRIL.

Stock Date P/S P/B P/E EV/EBIT
TRIL 2021-08-31 42000.0 7.0 53.3 48.2
TRIL 2021-08-30 42095.3 7.0 53.4 48.3
TRIL 2021-08-27 42218.6 7.0 53.6 48.5
TRIL 2021-08-26 42388.4 7.0 53.8 48.7
TRIL 2021-08-25 42267.4 7.0 53.7 48.5
TRIL 2021-08-24 42609.3 7.1 54.1 49.0

TRIL Growth Metrics

  • Its 5 year price growth rate is now at -59.82%.
  • The 2 year price growth rate now stands at -11.67%.
  • Its 2 year net cashflow from operations growth rate is now at -10.34%.
Over the past 33 months, TRIL's revenue has gone up $43,000.

The table below shows TRIL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.043 -37.884 33.872
2021-03-31 0.148 -32.658 -0.139
2020-12-31 0.148 -22.733 -59.346
2020-09-30 0.11195 -21.71675 -191.7016
2020-06-30 0.21282 -22.94372 -150.877
2020-03-31 0.124 -23.60278 -103.4682

TRIL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TRIL has a Quality Grade of D, ranking ahead of 19.03% of graded US stocks.
  • TRIL's asset turnover comes in at 0 -- ranking 437th of 677 Pharmaceutical Products stocks.
  • SEEL, ONCT, and IRWD are the stocks whose asset turnover ratios are most correlated with TRIL.

The table below shows TRIL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 1 0.697
2021-03-31 0.001 1 -0.002
2020-12-31 0.001 1 -1.898
2020-09-30 0.001 1 -8.481
2020-06-30 0.003 1 -11.896
2020-03-31 0.002 1 -28.139

TRIL Price Target

For more insight on analysts targets of TRIL, see our TRIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.88 Average Broker Recommendation 1.8 (Moderate Buy)

TRIL Stock Price Chart Interactive Chart >

Price chart for TRIL

TRIL Price/Volume Stats

Current price $17.53 52-week high $20.96
Prev. close $17.45 52-week low $5.80
Day low $17.38 Volume 703,900
Day high $17.55 Avg. volume 1,864,784
50-day MA $11.80 Dividend yield N/A
200-day MA $11.12 Market Cap 1.84B

Trillium Therapeutics Inc. (TRIL) Company Bio


Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.


TRIL Latest News Stream


Event/Time News Detail
Loading, please wait...

TRIL Latest Social Stream


Loading social stream, please wait...

View Full TRIL Social Stream

Latest TRIL News From Around the Web

Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Great Western Bancorp, Inc. (NYSE: GWB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Interstate BancSystem, Inc. Under the terms of the agreement, Great Western shareholders will receive 0.8425 shares of First Interstate Class A common stock for each Great Wester

Yahoo | September 23, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and VNE Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | September 21, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADTN, DSPG, LMRK, TRIL; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | September 17, 2021

New Strong Sell Stocks for September 15th

ARCE, NSSC, PAGP, TRIL, and VALE have been added to the Zacks Rank #5 (Strong Sell) List on September 15, 2021.

Yahoo | September 15, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and STMP Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | September 14, 2021

Read More 'TRIL' Stories Here

TRIL Price Returns

1-mo 0.81%
3-mo 64.91%
6-mo 73.05%
1-year 28.24%
3-year 187.38%
5-year 18.37%
YTD 19.17%
2020 1,328.16%
2019 -39.77%
2018 -76.41%
2017 28.32%
2016 -55.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9215 seconds.